In this video, a mother of two sons with Duchenne Muscular Dystrophy talks about only one of her sons meeting the inclusion criteria and qualifying for the study as well as her naivety about how often timelines in studies change.  She explains a double-blind placebo study and how in her son’s study, all the participants began receiving the drug once evidence proved safety and efficacy. She talks about the FDA process and the importance of knowing the sponsors plan for the period of time between study completion and approval of the treatment.